PCI Pharma is the latest pharmaceutical firm to set its post-Brexit hedge in Ireland
The company announced a new investment in its Meath-based facility.
AS BRITAIN HEADS towards Brexit in October, another pharmaceutical company has shored up its European operations in Ireland.
PCI Pharma Services has announced that it is investing in an expanded facility in Meath to ensure the continued flow of its business after Britain leaves the EU.
The Philadelphia-headquartered company provides outsourced services to the pharmaceutical sector, such as early-stage development and product packaging.
It will build a new 75,000 square foot clinical facility that will serve as a distribution centre for packaging, storage and logistics for investigational medicinal products, which is medicine that is being used in a clinical trial.
PCI already has a presence in Ireland as in 2018 it announced that it was adding 120 jobs in Louth and Meath. The latter facility is a result of PCI’s acquisition of Meath-based Millmount Healthcare in 2017.
The company did not disclose how much it was investing as part of its latest plan.
Salim Haffar, its chief executive, said that PCI was investing in global expansion to “support growing demand from our customers and providing a solution for Brexit through ongoing investment in capacity, capability expansion and talent”.
PCI, which has three facilities in the UK, is one of many firms active in Europe that have sought alternatives to their UK-based operations.
UK company Almac revealed a €34 million investment in its Dundalk base early last year to complement its facility in Armagh and “address any potential challenges that may arise due to Brexit”.
Get our Daily Briefing with the morning’s most important headlines for innovative Irish businesses.
